DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194 % ...

DexCom, Inc. (DXCM), headquartered in San Diego, California, is a leading medical-device company that designs, develops and ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom reported revenue of $1.21 billion in the third quarter, up 22% year over year, with U.S. revenue growing by 21% and international revenue growing by 22%. Adjusted net income was $0.61 per share ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...

NEW YORK, NY - November 6, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on ...

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...